PMC:7652766 / 77936-79226 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T381","span":{"begin":0,"end":286},"obj":"Sentence"},{"id":"T382","span":{"begin":287,"end":464},"obj":"Sentence"},{"id":"T383","span":{"begin":465,"end":735},"obj":"Sentence"},{"id":"T384","span":{"begin":736,"end":941},"obj":"Sentence"},{"id":"T385","span":{"begin":942,"end":1290},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Another therapeutic strategy using antibodies is intravenous immunoglobulin (IVIg) that contains polyclonal IgG isolated from healthy donors, which can be further enhanced by using IgG antibodies collected from recovered COVID-19 patients in the same geographical region as the patient. Results have been mostly positive, although many of these therapies have not been formally evaluated through a randomized, double-blind, placebo-controlled clinical trial (278). According to recent studies, IVIg can be used effectively in early stages of SARS-CoV-2 infection (before the initiation of systemic damage), reducing the use of mechanical ventilation, preventing the progression of pulmonary lesions, and promoting early recovery (268). Also, cross-neutralization activity was shown against SARS-CoV-2 in commercial IVIg manufactured prior to the COVID-19 pandemic and are currently under evaluation as potential therapies for COVID-19 (279). Thus, intravenous use of immunoglobulins can prove helpful in therapy against SARS-CoV-2, however, adjustments in the therapeutic regimen are necessary for all IVIg possibilities, as well as a complete understanding of the possible adverse effects, such as the risk of ADE (278, 279), that are being studied in more than 10 ongoing clinical trials."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2835","span":{"begin":839,"end":841},"obj":"Gene"},{"id":"2836","span":{"begin":475,"end":477},"obj":"Gene"},{"id":"2837","span":{"begin":230,"end":238},"obj":"Species"},{"id":"2838","span":{"begin":278,"end":285},"obj":"Species"},{"id":"2839","span":{"begin":790,"end":800},"obj":"Species"},{"id":"2840","span":{"begin":1020,"end":1030},"obj":"Species"},{"id":"2841","span":{"begin":1133,"end":1134},"obj":"Gene"},{"id":"2842","span":{"begin":396,"end":397},"obj":"Gene"},{"id":"2843","span":{"begin":221,"end":229},"obj":"Disease"},{"id":"2844","span":{"begin":542,"end":562},"obj":"Disease"},{"id":"2845","span":{"begin":681,"end":698},"obj":"Disease"},{"id":"2846","span":{"begin":846,"end":854},"obj":"Disease"},{"id":"2847","span":{"begin":926,"end":934},"obj":"Disease"}],"attributes":[{"id":"A2835","pred":"tao:has_database_id","subj":"2835","obj":"Gene:6999"},{"id":"A2836","pred":"tao:has_database_id","subj":"2836","obj":"Gene:6999"},{"id":"A2837","pred":"tao:has_database_id","subj":"2837","obj":"Tax:9606"},{"id":"A2838","pred":"tao:has_database_id","subj":"2838","obj":"Tax:9606"},{"id":"A2839","pred":"tao:has_database_id","subj":"2839","obj":"Tax:2697049"},{"id":"A2840","pred":"tao:has_database_id","subj":"2840","obj":"Tax:2697049"},{"id":"A2841","pred":"tao:has_database_id","subj":"2841","obj":"Gene:351"},{"id":"A2842","pred":"tao:has_database_id","subj":"2842","obj":"Gene:351"},{"id":"A2843","pred":"tao:has_database_id","subj":"2843","obj":"MESH:C000657245"},{"id":"A2844","pred":"tao:has_database_id","subj":"2844","obj":"MESH:C000657245"},{"id":"A2845","pred":"tao:has_database_id","subj":"2845","obj":"MESH:D008171"},{"id":"A2846","pred":"tao:has_database_id","subj":"2846","obj":"MESH:C000657245"},{"id":"A2847","pred":"tao:has_database_id","subj":"2847","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Another therapeutic strategy using antibodies is intravenous immunoglobulin (IVIg) that contains polyclonal IgG isolated from healthy donors, which can be further enhanced by using IgG antibodies collected from recovered COVID-19 patients in the same geographical region as the patient. Results have been mostly positive, although many of these therapies have not been formally evaluated through a randomized, double-blind, placebo-controlled clinical trial (278). According to recent studies, IVIg can be used effectively in early stages of SARS-CoV-2 infection (before the initiation of systemic damage), reducing the use of mechanical ventilation, preventing the progression of pulmonary lesions, and promoting early recovery (268). Also, cross-neutralization activity was shown against SARS-CoV-2 in commercial IVIg manufactured prior to the COVID-19 pandemic and are currently under evaluation as potential therapies for COVID-19 (279). Thus, intravenous use of immunoglobulins can prove helpful in therapy against SARS-CoV-2, however, adjustments in the therapeutic regimen are necessary for all IVIg possibilities, as well as a complete understanding of the possible adverse effects, such as the risk of ADE (278, 279), that are being studied in more than 10 ongoing clinical trials."}